Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma
Authors
Amato, David A.Bruckner, Howard
Guerry, DuPont IV
Ash, Arlene S.
Falkson, Geoffrey
Borden, Ernest C.
Creech, Richard H.
Savlov, Edwin D.
Cunningham, Thomas J.
UMass Chan Affiliations
Department of Quantitative Health SciencesDocument Type
Journal ArticlePublication Date
1987-01-01Keywords
AdolescentAdult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
effects
Cyclophosphamide
Dactinomycin
Drug Evaluation
Female
Humans
Hydroxyurea
Male
Melanoma
Middle Aged
Mitolactol
Semustine
Biostatistics
Epidemiology
Health Services Research
Metadata
Show full item recordAbstract
In this Eastern Cooperative Oncology Group (ECOG) phase II study, dibromodulcitol (DBD) and a combination of actinomycin D, hydroxyurea, and cyclophosphamide (AHC) were compared with methyl-CCNU, the current ECOG standard, in patients who had received no prior chemotherapy for disseminated malignant melanoma. The response rates were 6% (3/50) for AHC, 9% (3/34) for DBD, and 14% (7/49) for methyl-CCNU. Median survival times were 4, 5, and 6 months, respectively. Neither regimen appears to offer any advantage over methyl-CCNU as front-line therapy for patients with disseminated melanoma.Source
Invest New Drugs. 1987;5(3):293-7. Link to article on publisher's siteDOI
10.1007/BF00175301Permanent Link to this Item
http://hdl.handle.net/20.500.14038/47484PubMed ID
3667165Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1007/BF00175301